References
- Allegra E, Garozzo A, Lombardo N, De Clemente M, Carey TE. (2006). Mutations and polymorphisms in mitochondrial DNA in head and neck cancer cell lines. Acta Otorhinolaryngol Ital 26:185--90
- Bai RK, Leal SM, Covarrubias D, Liu A, Wong LJC. (2007). Mitochondrial genetic background modifies breast cancer risk. Cancer Res 67:4687--94
- Bandy B, Davison AJ. (1990). Mitochondrial mutations may increase oxidative stress: Implications for carcinogenesis and aging. Free Radic Biol Med 8:523--9
- Cai FF, Kohler C, Zhang B, Chen WJ, Barekati Z, Garritsen HS, Lenner P, et al. (2011). Mutations of mitochondrial DNA as potential biomarkers in breast cancer. Anticancer Res 31:4267--71
- Choi SJ, Kim S H, Kang HY, Lee J, Bhak JH, Sohn I, Jung SH, et al. (2011). Mutational hotspots in the mitochondrial genome of lung cancer. Biochem Biophys Res Commun 407:23--7
- Cogswell PC, Guttridge DC, Funkhouser WK, Baldwin Jr AS. (2000). Selective activation of NF-kappa B subunits in human breast cancer: Potential roles for NF-kappa B2/p52 and for Bcl-3. Oncogene 19:1123--31
- Czarnecka AM, Kukwa W, Krawczyk T, Scinska A, Kukwa A, Cappello F. (2010). Mitochondrial DNA mutations in cancer – From bench to bedside. Frontiers Biosci: J Virtual Library 15:437--60
- Haruta S, Furukawa N, Yoshizawa Y, Tsunemi T, Nagai A, Kawaguchi R, Tanase Y, et al. (2011). Molecular genetics and epidemiology of epithelial ovarian cancer (Review). Oncol Rep 26:1347--56
- Herod JJO, Eliopoulos AG, Warwick J, Niedobitek G, Young LS, Kerr DJ. (1996). The prognostic significance of Bcl-2 and p53 expression in ovarian carcinoma. Cancer Res 56:2178--84
- Hunn J, Rodriguez GC. (2012). Ovarian cancer: Etiology, risk factors, and epidemiology. Clin Obstetr Gynecol 55:3--23
- Jakupciak JP, Wang W, Markowitz ME, Ally D, Coble M, Srivastava S, Matria A, et al. (2005). Mitochondrial DNA as a cancer biomarker. J Mol Diagn 7:258–67
- Jin Y, Yu Q, Zhou D, Chen L, Huang X, Xu G, Huang J, et al. (2012). The mitochondrial DNA 9-bp deletion polymorphism is a risk factor for hepatocellular carcinoma in the Chinese population. Genetic Test Mol Biomarkers 16:330--4
- Lee HC, Li SH, Lin JC, Wu CC, Yeh DC, Wei YH. (2004). Somatic mutations in the D-loop and decrease in the copy number of mitochondrial DNA in human hepatocellular carcinoma. Mutat Res 547:71--8
- Penta JS, Johnson FM, Wachsman JT, Copeland WC. (2001). Mitochondrial DNA in human malignancy. Mutat Res 488:119–33
- Sanchez-Cespedes M, Parrella P, Nomoto S, Cohen D, Xiao Y, Esteller M, Jeromino C, et al. (2001). Identification of a mononucleotide repeat as a major target for mitochondrial DNA alterations in human tumors. Cancer Res 61:7015--19
- Taanman JW. (1999). The mitochondrial genome: Structure, transcription, translation and replication. Biochim Biophys Acta 1410:103--23
- Wang C, Zhang F, Fan H, Peng L, Zhang R, Liu S, Guo Z. (2011). Sequence polymorphisms of mitochondrial D-loop and hepatocellular carcinoma outcome. Biochem Biophys Res Commun 406:493–6
- Zhang R, Wang R, Zhang F, Wu C, Fan H, Li Y, Wang C, et al. (2010a). Single nucleotide polymorphisms in the mitochondrial displacement loop and outcome of esophageal squamous cell carcinoma. J Exp Clin Cancer Res 29:155--9
- Zhang R, Zhang F, Wang C, Wang S, Shiao YH, Guo Z. (2010b). Identification of sequence polymorphism in the D-Loop region of mitochondrial DNA as a risk factor for hepatocellular carcinoma with distinct etiology. J Exp Clin Cancer Res 29:130--6